Moh'd Khushman, MD
Medical Oncology · Saint Louis, MONPI 1750546735
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,325 of the $83,796 with a category attached, or 60.1%. 24 manufacturers reported payments, led by AstraZeneca at 49.4% of the total. Reporting peaked in 2020 at $29,243 and has fallen 61.1% since, to $11,385 in 2025. Among medical oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $741.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$41K
- Array Biopharma Inc$13K
- E.r. Squibb & Sons, L.L.C.$8K
- Exelixis Inc.$5K
- AbbVie$4K
- Pfizer$3K
- plus $9K from 18 others
Across 132 payments — averaging $11,149 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$494K
- AbbVie$332K
- Ipsen Bioscience Inc.$238K
- Incyte Corporation$144K
- AstraZeneca$139K
- E.r. Squibb & Sons, L.L.C.$55K
- plus $68K from 4 others
What the payments were for
- Consulting fees$25,62831%
- Speaking & faculty fees$50,32560%
- Travel & lodging$3,9545%
- Food & beverage$3,8775%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $41,400 |
| Array Biopharma Inc | 7 | $13,288 |
| E.r. Squibb & Sons, L.L.C. | 4 | $7,902 |
| Exelixis Inc. | 9 | $5,440 |
| AbbVie | 3 | $4,088 |
| Pfizer | 5 | $2,709 |
| Taiho Oncology, Inc. | 1 | $1,875 |
| Merck | 6 | $1,246 |
| Trisalus Life Sciences, Inc. | 2 | $1,212 |
| Bayer | 2 | $1,125 |
| Astrazeneca UK Limited | 9 | $1,071 |
| Caris MPI, Inc. | 3 | $829 |
| Ipsen Biopharmaceuticals, Inc | 7 | $626 |
| Novartis | 4 | $301 |
| Eisai Inc. | 4 | $181 |
| Bristol Myers Squibb | 2 | $157 |
| Tempus AI, Inc | 1 | $94 |
| Lilly USA, LLC | 1 | $86 |
| Astellas Pharma US Inc | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Genentech, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$36,480
- BRAFTOVI$15,944
- TAGRISSO$3,825
- TAS-102$1,875
- Cabometyx$1,481
- TRINAV INFUSION SYSTEM$1,212
- Stivarga$1,125
- KEYTRUDA$1,106
- ONIVYDE$226
- MI CANCER SEEK$200
- Abraxane$140
- MEKTOVI$103
- SOMATULINE DEPOT$101
How this compares
$83,796 in reported general payments places this provider in the 90th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 29 | $68,405 |
| EliquisApixaban | 55 | $36,998 |
| XareltoRivaroxaban | 19 | $11,298 |
| Prochlorperazine Maleate | 94 | $3,060 |
| Oxycodone Hcl | 105 | $1,869 |
| Ondansetron Hcl | 80 | $1,500 |
| Morphine Sulfate ErMorphine Sulfate | 41 | $1,328 |
| Sucralfate | 11 | $945 |
| Lidocaine Hcl ViscousLidocaine Hcl | 48 | $905 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 23 | $564 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 39 | $557 |
| LoperamideLoperamide Hcl | 45 | $538 |
| Pantoprazole Sodium | 20 | $536 |
| Ondansetron OdtOndansetron | 30 | $409 |
| Triamcinolone Acetonide | 18 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $4,088 | $68,40529 claims |
| PfizerEliquis | $2,709 | $36,99855 claims |
| Lilly USA, LLCOlanzapine | $86 | $27724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in Saint Louis
- Brad KahlSaint Louis$336K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
- Maurice WillisSaint Louis$101K
- Camille AbboudSaint Louis$70K
- Bruce RothSaint Louis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.